Brought to you by 
Exelixis acquires X-Ceptor Therapeutics for cash and stock
28 Oct 2004
Executive Summary
In a deal valued at about $24mm, genomics company Exelixis is acquiring all the outstanding stock (fully diluted) of privately held X-Ceptor Therapeutics (develops small-molecule modulators of nuclear hormone receptors--NHRs) for about $2.9mm in cash and 2.5mm of its common shares (valued at $8.43 apiece).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Exelixis acquires X-Ceptor Therapeutics for cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice